Presentations and Publications

Quantitative assessment of the tumor microenvironment using the Aurora™ 3D Spatial Biology Platform | Abstract | Poster | sITC 2023

DDR1 expression is associated with a worse prognosis in intrahepatic cholangiocarcinoma | Abstract | Poster | SITC 2023

The epithelium-stroma interface serves as a barrier to immune cell infiltration across tumor immune phenotypes in epithelial cancers | Abstract | Poster | sITC 2023

Comparison of multiplex immunofluorescence and H&E-based approaches for characterization of the tumor microenvironment | Abstract | Poster | sITC 2023

A phase 1 first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies | Abstract | Poster | ESMO Congress 2023

High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment | Abstract | Poster | ESMO Congress 2023

A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer | Article | May 26, 2023 | Journal for ImmunoTherapy of Cancer

Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop | Article | April 28, 2023 | Journal for ImmunoTherapy of Cancer

Towards a consensus definition of immune exclusion in cancer | Article | March 22, 2023 | Frontiers in Immunology

High Prevalence of Immune exclusion in Cancer as Determined by Pathologist Assessment and Image Analysis | Abstract | Poster | AACR 2023

Discoidin Domain Receptor 1 Expression is Associated with Stroma TGF-beta Signaling in Selected Cancers | Abstract | Poster | SITC 2022

Cancer-Associated Fibroblasts Correlate with Immune Phenotypes in Human Tumors | Abstract | Poster | ESMO Congress 2022

Tumour DDR1 Promotes Collagen Fibre Alignment to Instigate Immune Exclusion | Article | November 3, 2021 | Nature